Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

ISSN: 1875-5666 (Online)
ISSN: 1566-5240 (Print)

Volume 16, 10 Issues, 2016

Download PDF Flyer

Current Molecular Medicine

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 33rd of 123 in Medicine, Research & Experimental

Submit Abstracts Online Submit Manuscripts Online

David W. Li
College of Medicine
University of Nebraska Medical Center
Omaha, NE

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.621
5 - Year: 3.788

Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

Current Molecular Medicine, 14(3): 376-384.

Author(s): X. Zhang, N. Wang, A.P. Schachat, S. Bao and MC Gillies.

Affiliation: Beijing Institute of Ophthalmology, Tongren Eye Centre, Tongren Hospital, Ophthalmology & Visual Sciences Key Lab,Capital Medical University, 100730, P.R. China.


Diabetic retinopathy (DR) is one of the leading causes of blindness in the working population worldwide. Vascular leakage, angiogenesis and neuronal degeneration are key features of DR. Current effective interventions for DR include treatment of systemic risk factors such as elevated blood glucose, blood pressure and dyslipidemia. Ocular treatments include vascular endothelial growth factor A (VEGF-A) inhibitors, laser photocoagulation and surgery. While anti-VEGF therapy has become as first-line treatment for diabetic macular edema (DME) that causes reduced vision, intravitreal glucocorticoids also have been shown to be efficacious in this situation. It has been reported that all the major pathological processes of DR are susceptible to glucocorticoid treatment. The effects of glucocorticoids on vascular leakage and angiogenesis may be mediated through their well established anti-inflammatory role. Alternatively, glucocorticoids may affect other mechanisms known to be activated in DR. Potential mechanisms for the anti-inflammatory effects of glucocorticoids include blockage of cytokine production and inhibition of leukocyte adhesion induced by VEGF-A. Glucocorticoids decrease the expression of VEGF-A directly, and increase the production, or decrease phosphorylation, of tight junction-associated proteins. Glucocorticoids have also been shown to be neuroprotective, in contrast to VEGF-A inhibitors which animal studies suggest may be neurotoxic. This review outlines the biological properties of synthetic glucocorticoids, with particular emphasis on the potential beneficial effect of combining glucocorticoids with anti-VEGF treatment for DME and DR.


Diabetic retinopathy, glucocorticoids, glucocorticoid receptors, neuronal protection.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 3
First Page: 376
Last Page: 384
Page Count: 9
DOI: 10.2174/1566524014666140128114414

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science